MCP also significantly reduced levels of fasting blood glucose, diastolic blood pressure, mean arterial pressure, serum triglycerides, total cholesterol, LDL, free fatty acids, but increased levels of HDL and adiponectin, the insulin sensitivity and insulin secretion indices, indicating that treatment with MCP improves glucose and lipid metabolism profiles, insulin sensitivity, renal function, and hypertension management in patients with T2DM and hypertension, thereby suggesting that MCPs may be used in patients with both T2DM and hypertension [168]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.